Mortaza Raeisi

Mortaza Raeisi

Auto-generated profile, based on publicly available information

Mortaza Raeisi


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2021 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
ANAmirreza Naseri
Amirreza Naseri
HSHanieh Salehi-Pourmehr
Hanieh Salehi-Pourmehr
RMReza Majidazar
Reza Majidazar
PSParya Seraji
Parya Seraji
ERErfan Rezazadeh-Gavgani
Erfan Rezazadeh-Gavgani
MRMortaza Raeisi
Mortaza Raeisi

1 August 2017
Verified
Journal Article
Open access
PDF file
HCHadi Chavoshi
Hadi Chavoshi
Vahid VahedianVahid Vahedian
Vahid Vahedian
SSSomaiyeh Saghaei
Somaiyeh Saghaei
MPMohammad Bagher Pirouzpanah
Mohammad Bagher Pirouzpanah
MRMortaza Raeisi
Mortaza Raeisi
NSNasser Samadi
Nasser Samadi
Herbal-derived medicines have introduced as sources of novel drugs due to minimum systemic side effects. Silibinin as a flavonoid compound has showed with effective chemotherapeutic effects on different cancers. Here, we investigated the impact of combination therapy of silibinin, with paclitaxel and cisplatin in inhibition of proliferation and induction of apoptosis in MCF-7 cells. Cell proliferation was assessed by MTT assay and the percentage of apoptotic cells was measured using flowcytometric assay. Understand of molecular mechanism of this combination related to apoptotic pathway were evaluated by Real Time RT-PCR assays. The IC50 values for silibinin, paclitaxel and cisplatin were 160 ± 22.2 μM, 33.7 ± 4.2 nM and 3.2 ± 0.5 μM, respectively. Paclitaxel and cisplatin induced higher percentage of apoptosis in MCF-7 (P < 0.05). Treatment of cell line with combination of silibinin and paclitaxel or cisplatin showed enhanced early apoptosis 56% and 61%, respectively (P < 0.05). Gene expression patterns demonstrated a significant decrease in anti-apoptotic Bcl-2 with increase in pro-apoptotic Bax, P53, BRCA1 and ATM mRNA levels. Taken together combination therapy of breast cancer cells by applying paclitaxel or cisplatin with silibinin synergistically increases the anti-proliferative effect of single agents.

1 December 2018 in Prostate International
Verified
Journal Article
Open access
MMMohammad Mohammadzadeh
Mohammad Mohammadzadeh
MSMasoud Shirmohammadi
Masoud Shirmohammadi
MGMorteza Ghojazadeh
Morteza Ghojazadeh
LNLeila Nikniaz
Leila Nikniaz
MRMortaza Raeisi
Mortaza Raeisi
SASeyed Ali Mousavi Aghdas
Seyed Ali Mousavi Aghdas
Dendritic cells (DCs) are used in many malignancies as vaccines to induce immunity against specific cancer antigens. The role of DCs in metastatic castration-resistant prostate cancer (mCRPC) is not determined. In this study, the proportion of mCRPC patients with clinically significant response to targeted therapy by DCs pulsed with prostate-specific membrane antigen was evaluated, and the possible adverse effects of this modality were investigated. Major databases were searched up to Feb 2017, to identify studies in which the antitumor efficacy of DCs pulsed with the extracellular portion of PSMA was studied for the treatment of mCRPC. Data were collected by two reviewers and analyzed using Comprehensive Meta-Analysis software, version 2.0. Our study consisted of 6 nonrandomized prospective (cohort) trials, overall reporting on 153 mCRPC patients. The event rate that is the representative of fraction of patients showing antitumor response was 0.43 (95% confidence interval = 0.355-0.512; P = 0.097). No significant between-study heterogeneity or inconsistency was detected (I2 = 5.47; Q = 5; P = 0.382). Our study failed to demonstrate a significant therapeutic efficacy for DCs in mCRPC. However, no significant adverse effects were seen.

1 January 2024 in Russian Journal of Electrochemistry
Verified
Journal Article
Closed access
PDF file
MZMojtaba Zehtabi
Mojtaba Zehtabi
MRMortaza Raeisi
Mortaza Raeisi
Gastric cancer (GC) is one of the considered enormously important cancer types in the world. A large number of mortality rates have revealed that there is a massive shortage in the prognosis and treatment of GC because the majority of GC cases are identified at an advanced stage. In this regard, the rapid platform for non-invasive detection of GC cells through the analysis of GC biomarkers in the first stages with high sensitivity is essential for the success in the treatment of GC. In recent years, different types of electrochemical immunosensors as efficient sensing devices with benefits including accuracy, reproducibility and low cost have played an extremely significant role in the monitoring of GC. One of the significant issues in the development of electrochemical immunosensors is to increase the system’s sensitivity. A variety of nanomaterials based on carbon-based, silica-based and metallic-based nanomaterials have been used as sensing platforms on the different types of electrochemical electrodes for improving the properties of biodevices. This review highlighted the new progress and technical breakthroughs comprising electrochemical immunosensor for the determination of GC biomarkers including CA19-9, CA72-4, CA125 and CEA. In diverse matrices and proved how nanoprobes could enhance the performance of electrochemical immunsensing approaches.

1 September 2022
Verified
Journal Article
Closed access
SVSepehr Valizadeh
Sepehr Valizadeh
MZMojtaba Zehtabi
Mojtaba Zehtabi
NFNeda Feiziordaklou
Neda Feiziordaklou
ZAZahra Akbarpour
Zahra Akbarpour
AKAmir Mahdi Khamaneh
Amir Mahdi Khamaneh
MRMortaza Raeisi
Mortaza Raeisi

1 September 2019 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
MRMortaza Raeisi
Mortaza Raeisi
ANAli Reza Nikhanfar
Ali Reza Nikhanfar
BNBabak Nejate
Babak Nejate
AAAli Akabr Movassaghpour Akbari
Ali Akabr Movassaghpour Akbari
RDRoya Dolatkhah
Roya Dolatkhah
ZSZohreh Sanaat
Zohreh Sanaat
Background: The key proliferative RTKs for AML include c-KIT receptor (CD117) and FLT-3 receptor (CD135).The aim of this study was to evaluate the CD135 and CD117 expression, co-expression of CD135 and CD117(CD135+CD117), and the association of that co-expression with Event Free Survival (DFS) and Overall Survival (OS)rates. Material and Methods: We analyzed CD117 and CD135 expression on AML blasts by flow cytometry and itsassociation with Event Free Survival (DFS) and Overall Survival (OS) in 66 AML treated on Hematology-OncologyResearch Center, Iran, Tabriz. Results: The overall OS and EFS were 50% and 80.3% respectively during our study.Cox-regression analysis revealed that a poor EFS was significantly associated a low CD135 (HR 0.34, 95% CI0.13–0.88, P = 0.02). Conclusion: This is the first study from Iran to show that the expressions of CD135, CD117 iseasily measurable by routine diagnostic flow-cytometry, and CD135+117 were not significantly associated with CR,EFS, or OS .